Multiple Myeloma

The meeting will focus on the basic, preclinical, and clinical aspects of myeloma, including precursor disease, high-risk disease, immunotherapies, novel biomarkers, and more.

The decision expands treatment options for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM).

The efficacy and safety profiles of CAR T-cell and bispecific antibody therapies have led to their investigation in earlier lines of therapy, with several new treatments in development.

Researchers suggest prior treatments and follow-up duration may play a larger role.

The evolving treatment landscape for multiple myeloma includes debates on the timing and effectiveness of CAR T-cell therapy and quadruple immunotherapy regimens.

Mary McGann, PharmD, BCOP, offers insights into CAR T-cell therapy and the crucial role of pharmacists in mitigating resistance.

Accurate, effective screening is crucial for connecting patients with needed financial resources and support.

Patients can face barriers to BCMA-targeted treatments.

CAR T-cell therapy in multiple myeloma faces challenges from the immunosuppressive cells in the tumor microenvironment.

Isatuximab (Sarclisa; Sanofi) in combination with standard-of-care significantly improved progression-free survival in patients with newly diagnosed multiple myeloma.

CD38 density may indicate the efficacy of monoclonal antibody treatment in patients with multiple myeloma.

The decision is based on positive results from the PERSEUS trial.

Early identification of monoclonal gammopathy of undetermined significance leads to more efficacious disease monitoring and intervention.

Increased levels of absolute lymphocyte count are associated with improved response to BCMA-targeted CAR T-cell therapy.

β2-microglobulin may be an effective indicator of coagulation dysfunction in patients with newly diagnosed multiple myeloma (NDMM).

IMROZ study data show Isa-VRd may be a new standard of care.

Radiotherapy may have applications beyond symptomatic relief when used in combination with immunotherapy.

Researchers identify significant proteins involved in the growth and survival of malignant multiple myeloma cells.

Chimeric antigen receptor (CAR) T-cell therapy can engineer T cells to target malignant cells in multiple myeloma.

The monotherapy is compared with the combination regimen of elotuzumab plus pomalidomide and dexamethasone in adult patients with relapsed or refractory multiple myeloma.

An interdisciplinary discussion addresses the disparity in availability and use of these therapies across the continuum of care.

The quadruplet regimen added bortezomib to the current standard of care, which is a triplet regimen of isatuximab, lenalidomide, and dexamethasone for patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM TI).

Observation time on subsequent injections of subcutaneous daratumumab may be safely removed from institutional policies to reduce chair time.

Amplification of chromosome 1q is associated with poorer treatment outcomes for patients with relapsed/refractory and newly diagnosed multiple myeloma.

The study showed that belantamab mafodotin plus pomalidomide and dexamethasone (BPd) significantly improved progression-free survival compared to pomalidomide plus bortezomib and dexamethasone (PVd).